Pharmacokinetic, Safety/Tolerability Study of a Single SC Dose of PB1023 Injection in Subjects With Normal and Impaired Renal Function

Inclusion Criteria:

- Males and females age 18 - 79 years of age inclusive.

- BMI 19 - 40 kg/m2.

- Renally Impaired Subjects: In otherwise stable health except for Renal Disease.

- Healthy volunteers must have/be: eGFR as calculated by MDRD of ≥ 80 mL/min, and
Matched to renally impaired subjects for age (± 10 years), weight (± 10 kg), and if
possible BMI, race and gender.

- Subjects with renal impairment must have 2 separate eGFR that are within 20% of each
other and clinically stable for a minimum of 6 months.

- No clinically relevant abnormalities in the results of the laboratory screening or
admission evaluation other than those consistent with renal impairment or related
disease/disorder in the appropriate subject group as determined by the Investigator.

Exclusion Criteria:

- Currently taking or have taken a GLP -1 agent (e.g., Byetta®, Victoza®) within the
past year.

- Subjects who have previously received PB1023.

- Known allergy or serious adverse effect to an approved or investigational GLP-1
receptor analog/agonist.

- Serious Infection within 60 days of admission.

- Donation or loss of greater than 400 mL of blood 56 days prior to enrollment.

- Unstable cardiovascular disease defined as per protocol.

- Clinically significant hepatic dysfunction defined as per protocol.

- Female subjects who are pregnant, trying to become pregnant or lactating.

- Known history of or active alcohol or drug abuse within 12 months prior to Screening
or positive alcohol and/or drug screen.

- Positive for Human Immunodeficiency Virus (HIV) antibodies, Hepatitis B surface
antigen (HBsAg) or Hepatitis C Virus (HCV) antibodies.

- Participating in any other study at time of screening other than observational
studies or have received any other investigational drug or device within 30 days or 5
half-lives prior to dosing or are taking part in a non-drug study which in the
opinion of the Investigator would interfere with the outcome of the study.